Recombinant Human CD30 / TNFRSF8 Protein, Llama IgG2b Fc Tag, low endotoxin, 100 µg

Background
Human CD30 is also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. TNFRSF-8 is expressed by activated, but not by resting, T and B cells. Also, CD30 is expressed on classical Hodgkin Lymphoma cells together with CD15. CD30 is the receptor for TNFSF8/CD30L. CD30 can interact with TRAF2 and TRAF5, and mediate the signal transduction that leads to the activation of NF-kappa-B. TNFRSF8 may play a role in the regulation of cellular growth and transformation of activated lymphoblasts. TNFRSF8 is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.

Source
Recombinant Human CD30, Llama IgG2b Fc Tag, low endotoxin (TN8-H5250) is expressed from human 293 cells (HEK293). It contains AA Phe 19 - Lys 379 (Accession # NP_001234.2).
Predicted N-terminus: Phe 19

Molecular Characterization
This protein carries a llama IgG2b Fc tag at the C-terminus.
The protein has a calculated MW of 66.3 kDa. The protein migrates as 95-120 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 0.01 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet

Clinical and Translational Updates

(1) "Whole slide imaging of tumour microenvironment in classical Hodgkin's lymphoma: development of a clinical prediction model based on programmed death-ligand 1 and tumorous Reed-Sternberg cells"
Santisteban Espejo, Bernal-Florindo, Montero-Pavon et al
J Clin Pathol (2023)
(2) "Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real-world study"
Zhang, Qiao, Chai et al
Cancer Med (2023)
(3) "Atypical Cutaneous Lymphoid Hyperplasia of Nose: A Pathological Puzzle"
Krishnakumar, Rajendran, Sindhu et al
Indian J Otolaryngol Head Neck Surg (2023) 75 (4), 3980-3983
Showing 1-3 of 5991 papers.